Northern Data Aktie 27392576 / DE000A0SMU87
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
10.11.2025 06:37:43
|
EQS-Adhoc: Northern Data Enters into a Business Combination Agreement with Rumble
|
EQS-Ad-hoc: Northern Data AG / Key word(s): Tender Offer/Tender Offer Disclosure of an inside information acc. to Article 17 of the Regulation (EU) No 596/2014 Northern Data Enters into a Business Combination Agreement with Rumble Frankfurt – 10 November 2025 – Northern Data AG (ETR: NB2) (“Northern Data”) today entered into a business combination agreement with Rumble Inc. (NASDAQ: RUM, “Rumble”) in connection with Rumble’s intention to make a tender offer (the “Proposed Offer”) for 100% of the outstanding shares of Northern Data. Each Northern Data shareholder who tenders its shares will receive 2.0281 shares of newly issued Rumble Class A common stock in exchange for each Northern Data share (with customary settlement mechanisms for fractional shares). In addition, the Proposed Offer provides for a potential cash payment to Northern Data shareholders who accept the Proposed Offer as well as other shareholders who have agreed to sell their shares to Rumble in an amount of up to USD 200 million (the “Cash Consideration Amount”). The Cash Consideration Amount will be due solely in the event there is a successful sale and commercialization of Northern Data’s previously owned Corpus Christi location to a leading global infrastructure asset management firm that is currently evaluating the location for HPC purposes under an exclusivity agreement. The Cash Consideration Amount payable, if any, will be calculated based on actual net proceeds received by Northern Data from such transaction prior to the closing of the Proposed Offer. The terms under which Corpus Christi could be developed for HPC were previously disclosed in a press release published on 3 November 2025. The launch of the Proposed Offer is subject to certain conditions expected to be satisfied during the first or second quarter of 2026. The agreements include significant additional commercial commitments to support Northern Data conditioned upon closing, in particular a customer agreement with Tether in an aggregate amount of up to USD 150 million for GPU leasing over a two-year term and a commitment to fund up to USD 200 million of any potential tax liabilities in cooperation with Rumble. At closing of the Proposed Offer, Northern Data’s currently outstanding approx. EUR 610 million shareholder loan will be acquired by Rumble (or a subsidiary thereof) from Tether and continue as an intercompany loan. In exchange, Tether will receive 50% of the loan balance as Rumble Class A common stock at a price per Rumble share of USD 7.88, with the remaining 50% being paid in the form of a new loan from Tether to Rumble (secured by assets of Northern Data). Tether has further agreed that prior to closing it will not terminate the existing shareholder loan and that the interest accrued on it will be capitalized. There is no minimum acceptance rate for the Proposed Offer. Tether, as well as an affiliate of the current CEO of Northern Data, Aroosh Thillainathan, and another large shareholder, who together own approximately 72% of Northern Data’s shares, have entered into support agreements for the transaction, pursuant to which they have agreed to sell their shares to Rumble on the same terms as in the Proposed Offer. Closing of these transactions would occur simultaneously with closing of the Proposed Offer. In the business combination agreement, Rumble and Northern Data have agreed that no domination and profit and loss transfer agreement will be concluded for a period of at least three years after closing of the Proposed Offer and that the inclusion of Northern Data’s shares in the open market (Freiverkehr) of the Munich Stock Exchange (and, if applicable, any other stock exchange) shall be terminated upon Rumble’s request after closing of the Proposed Offer. There will be no delisting offer. The launch of the Proposed Offer is expected to occur during the second quarter of 2026. The transaction is expected to close in the second quarter of 2026, subject to satisfaction of closing conditions and regulatory approvals. End of Inside Information
10-Nov-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Northern Data AG |
| An der Welle 3 | |
| 60322 Frankfurt/Main | |
| Germany | |
| Phone: | +49 69 34 87 52 25 |
| E-mail: | info@northerndata.de |
| Internet: | www.northerndata.de |
| ISIN: | DE000A0SMU87 |
| WKN: | A0SMU8 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Hanover, Munich (m:access), Stuttgart, Tradegate Exchange |
| EQS News ID: | 2226536 |
| End of Announcement | EQS News Service |
|
|
2226536 10-Nov-2025 CET/CEST
Nachrichten zu Northern Data AG
Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest
Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.
Schnell noch Plätze sichern!Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer
Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉
Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.
💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Shutdown-Ende in Sicht? SMI und DAX schlussendlich stärker -- Asiens Börsen letztlich in GrünDer heimische Aktienmarkt präsentierte sich am Montag mit Gewinnen. Anleger am deutschen Aktienmarkt wurden ebenso wieder mutiger. Die Wall Street beginnt die Woche fester. An den Märkten in Fernost ging es zum Wochenstart nach oben.


